alzheon.com
‘Gene-dose’ effect for Alzheon’s ALZ-801, a drug targeting Alzheimer’s disease
Closely-held US biotech firm Alzheon has announced the publication of data that shows for the first time a ‘gene-dose’ effect for a drug targeting Alzheimer’s disease to treat a subpopulation of up to 65% of Alzheimer’s patients with a genetic risk factor. Based on these results, Alzheon is advancing its drug candidate tramiprosate into Phase III